OXYGEN THERAPY
Oxygen Therapy is a biopharma company that develops anti-necrosis drugs that treat a variety of medical conditions resulting from Ischemia. The company focuses on the development and commercialization of first-in-class treatments to prevent catastrophic brain damage resulting from hypoxic conditions following a brain stroke. The Company’s lead product candidate, OTI-629, is an anti-necrosis drug that carries oxygen to tissues when the flow of blood is blocked. It will be tested as a potent resuscitative agent to treat Ischemic brain strokes, also known as Cardiac Cerebrovascular Accidents (CVA). In addition, their drug candidate OTI-1011, will be tested as a resuscitative agent in a variety of wound healing applications.
OXYGEN THERAPY
Industry:
Biopharma Pharmaceutical Therapeutics
Founded:
2016-01-01
Address:
Newton, Massachusetts, United States
Country:
United States
Website Url:
http://www.otipharma.com
Total Employee:
11+
Status:
Closed
Contact:
617-454-1199
Email Addresses:
[email protected]
Total Funding:
300 K USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager Google Universal Analytics Euro
Current Advisors List
Current Employees Featured
Founder
Official Site Inspections
http://www.otipharma.com
- Host name: a904c694c05102f30.awsglobalaccelerator.com
- IP address: 76.223.54.146
- Location: Seattle United States
- Latitude: 47.54
- Longitude: -122.3032
- Metro Code: 819
- Timezone: America/Los_Angeles
- Postal: 98108
More informations about "Oxygen Therapy"
HOME - OBI Pharma 台灣浩鼎
OBI-992 Shortlisted as the Most Promising Clinical Candidate in the 11th Annual World ADC Awards. OBI Pharma, Inc. (4174.TWO), a clinical-stage oncology company, announced that OBI-992, a TROP2 targeted antibody-drug …See details»
Corporate Overview - OBI Pharma 台灣浩鼎
Apr 29, 2002 OBI Pharma, Inc. Stock Code 4174.TWO Market Taipei Exchange Industry Type Biotech & Medical Care Principal Activities New drugs research Date of Establishment …See details»
OBI Pharma - LinkedIn
OBI Pharma Inc. (OBI) is a global clinical stage oncology company that is headquartered in Taiwan. The company also has subsidiaries in the United States and Australia. It was founded in 2002 by ...See details»
OBI Pharma, Inc. - Wikipedia
The company was founded by Micheal N.Chang on April 29, 2002. It was formerly a subsidiary of Optimer Pharmaceuticals. On 9 Feb 2007, its parent company Optimer Pharmaceuticals can buy/sell on Nasdaq Stock Exchange. At that time, its share price was US$8.50 per share. On 15 May 2012, OBI Pharma, Inc. was approved to become a public company in Taiwan. See details»
OBI Pharma USA - LinkedIn
OBI Pharma USA, Inc. (OBI USA) is the wholly-owned subsidiary of OBI Pharma, Inc. (4174.TWO) OBI USA’s mission is to lead the US and European clinical trials of OBI’s novel …See details»
Company OBI Pharma, Inc. - MarketScreener.com
Feb 6, 2013 OBI Pharma, Inc. is a Taiwan-based company principally engaged in the development of new pharmaceuticals. The Company mainly operates its businesses through …See details»
OBI Pharma Announces Executive Leadership Management …
Jun 2, 2023 Additionally, with OBI’s innovative cancer pipeline under clinical trials to address unmet medical needs, it is an exciting time to join the organization,” stated Dr. Wang. Dr. …See details»
Who We Are - OBI Pharma 台灣浩鼎
Adagloxad Simolenin (OBI-822) was approved to carry out phase III human clinical trial in Poland and Brazil. OBI-833 was reviewed by Taiwan Food and Drug Administration (TFDA) of the Ministry of Health and Welfare and then …See details»
OBI Pharma, Inc. (Taiwan, China) - EMIS
May 26, 2024 Report with financial data, key executives contacts, ownership details & and more for OBI Pharma, Inc. in Taiwan, China. Report is available for immediate purchase & download …See details»
OBI PHARMA, INC. Company Profile - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for OBI PHARMA, INC. of Taipei City, Taipei. Get the latest business insights from Dun & Bradstreet.See details»
OBI Pharma - Overview, News & Similar companies | ZoomInfo.com
May 31, 2023 OBI Pharma contact info: Phone number: (619) 537-7698 Website: www.obipharma.com What does OBI Pharma do? OBI Pharma, Inc., is a Taiwan …See details»
OBI Pharma - Craft
Sep 25, 2024 OBI Pharma has 1 employees across 3 locations and NT$41.55 m in annual revenue in FY 2023. See insights on OBI Pharma including office locations, competitors, …See details»
Organization Operations - OBI Pharma 台灣浩鼎
In 2014, OBI Pharma established the “Corporate Social Responsibility Practice Code” as a governance regulation to ensure internal adherence to environmental and …See details»
OBI Pharma Announces Executive Leadership Management …
Jun 2, 2023 I am impressed with the dedication and accomplishments of the organization to date. Additionally, with OBI’s innovative cancer pipeline under clinical trials to address unmet …See details»
Biosion, Inc. Licenses BSI04702, An Anti-TROP-2 mAb, to OBI
Dec 13, 2021 Biosion, Inc. Licenses BSI04702, An Anti-TROP-2 mAb, to OBI Pharma, Inc. for Worldwide Development and Commercialization Rights as an Antibody Drug Conjugate and …See details»
OBI Pharma, Inc. (台湾浩鼎生技股份有限公司) - 药物管线_专利_临 …
了解OBI Pharma, Inc. (台湾浩鼎生技股份有限公司)公司的药物管线，治疗领域，技术平台，以及它的11项临床试验, 26篇新闻和43篇文献，疾病领域:肿瘤，技术平台:ADC，灭活疫苗，治疗 …See details»
企業文化 - OBI Pharma 台灣浩鼎
OBI 專注於癌症療法的創新研發，旨在開發 “first-in-class”和 […]See details»
OBI Pharma Enters License Agreement with Odeon Therapeutics …
Feb 22, 2022 Additional information can be found at www.obipharma.com. About Odeon Therapeutics. Odeon Therapeutics lnc., is an innovation-driven biopharmaceutical company …See details»
Investor Overview - OBI Pharma 台灣浩鼎
OBI-992 Ranks Among World ADC Award Top 8, Stands Strong Among Global Pharma Giants Despite Missing Top Prize, Gains Global RecognitionSee details»